Validity of assessing inhibitor development in haemophilia PUPs using registry data: The EUHASS project

Haemophilia

Volumn 18, Issue 3, 2012, Pages

  Fischer, K ^a,b   Lewandowski, D ^a   Marijke van den Berg, H ^a   Janssen, M P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Haemophilia; Inhibitor; Previously untreated patient; Registry; Study design

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR;

ARTICLE; CALCULATION; COHORT ANALYSIS; DISEASE REGISTRY; HEMOPHILIA A; HUMAN; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; REGISTRIES; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; VALIDATION STUDIES AS TOPIC;

EID: 84860320467     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02687.x     Document Type: Article

References (16)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
2. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
3. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
4. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8(Suppl 2): 23-9.
5. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
6. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
7. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
8. Iorio A, Matino D, D'Amico R, Makris M. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2010; 8: CD004449.
9. Lee ML, Roth DA. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia 2005; 11: 5-12.
10. van der Bom JG, ter Avest P, van den Berg HM, Psaty BM, Weiss NS. Assessment of incidence of inhibitors in patients with haemophilia. Haemophilia 2009; 15: 707-11.
11. Committee for Medicinal Products for Human Use (CHMP). Draft Guideline on the Clinical Investigation of Recombinant and Human Plasma-Derived Factor VIII Products. London: European Medicines Agency, 2009.
12. US Food Drug Administration (FDA). Office for Biologics Evaluation and Research and Office of Blood Research and Reviewe and the International Association for Biologicals. The Factor VIII Inhibitor Workshop. Bethesda: FDA, 2003.
13. Makris M, Calizzani G, Fischer K et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127(Suppl 2): S22-5.
14. Ter Avest PC, Fischer K, Mancuso ME et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost 2008; 6: 2048-54.
15. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005; 11: 92-9.
16. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.